Insights / Topic
Earnings
Decision-ready coverage built from the headline, the observed price path and volume confirmation. Pages update when new verified evidence becomes available.
Edwards Lifesciences rises 9.127% after Q2 adjusted EPS and revenue beat estimates
EW moved from a $82.50 pre-headline baseline to $90.03 in the measured post-market window as broad structural-heart growth accompanied higher full-year sales guidance.